Diane Pannier

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Yann Vano, Réza Elaidi, Mostefa Bennamoun et al. · The Lancet Oncology · 2022 · 136 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability

Olivier Bouché, Thierry André, Karine Le Malicot et al. · JAMA Oncology · 2023 · 43 citations · Full text

Medicine, Oncology, Pharmacology +17

A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

Jean‐Yves Blay, Camille Schiffler, Olivier Bouché et al. · Annals of Oncology · 2024 · 39 citations · Full text

Medicine, Oncology, Neoplasia +7

LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial

Yann Vano, R.T. Elaidi, Mostefa Bennamoun et al. · Annals of Oncology · 2020 · 29 citations

Medicine, Oncology, Pharmacology +17

Prolonged survival of patients with breast cancer-related leptomeningeal metastases.

Émilie Le Rhun, Sophie Taillibert, Fahed Zaïri et al. · PubMed · 2013 · 23 citations

Medicine, Oncology, Breast Oncology +9